Dr. Foss On Tipifarnib In Relapsed, Refractory, T-Cell Lymphoma

Dr. Foss on Tipifarnib in Relapsed, Refractory, T-Cell Lymphoma

Blood Cancers Today

iwNHL 2015 roundtable: Novel therapeutic combinations for relapsed/refractory T-cell lymphoma

VJHemOnc – Video Journal of Hematology & HemOnc

Predicting tipifarnib response in T-cell NHL

VJHemOnc – Video Journal of Hematology & HemOnc

Dr. Foss on the Unmet Need in Cutaneous T-cell Lymphoma

T-cell Lymphoma

The future of valemetostat in PTCL

VJHemOnc – Video Journal of Hematology & HemOnc

Novel developments in relapsed/refractory HL: checkpoint inhibitors, bispecifics and CAR-T cells

VJHemOnc – Video Journal of Hematology & HemOnc

Novel treatment strategies in T-cell lymphomas

VJHemOnc – Video Journal of Hematology & HemOnc

Relapsed / Refractory Diffuse Large B-Cell Lymphoma (DLBCL) with Dr Gareth Gregory

Lymphoma Australia

iwNHL 2015 roundtable: Improving treatment strategies for T-cell lymphoma

VJHemOnc – Video Journal of Hematology & HemOnc

Targeting chemokines in lymphoma

VJHemOnc – Video Journal of Hematology & HemOnc

PRIMO: Optimising the dose of duvelisib in patients with R/R peripheral T-cell lymphoma

Combining targeted agents with checkpoint inhibitors in cutaneous T-cell lymphoma

VJHemOnc – Video Journal of Hematology & HemOnc

Relapsed/Refractory Follicular Lymphoma Treatments and Bispecific Antibodies

Patient Empowerment Network

International Patient Conference 2021 - Fireside Chat with Francine Foss

CutaneousLymphomaFnd

Francine M. Foss, MD: Interview Part 1

HematologyTimes.com

Understanding Clinical Trials for Cutaneous Lymphoma

CutaneousLymphomaFnd

Debate: A Case of Relapsed Peripheral T-Cell Lymphoma - Sequential novel agents

T-cell lymphoma registries: What have we learned?

MDedge: news and insights for busy physicians

Update on Relapsed/Refractory Diffuse Large B-Cell Lymphoma | LRF Webinars

Lymphoma Research Foundation